

**Supplementary Table 1. Demographics and baseline characteristics**

	Placebo N=8	ACE-536 Treatment (mg/kg)				Overall N=32
		0.0625 N=6	0.125 x 1 N=6	0.125 x 2 N=6	0.25 N=6	
<b>Age (yr), mean (SD), range</b>	58.6 (4.7) 55-69	59.3 (7.5) 49-69	57.7 (5.8) 52-68	60.5 (2.6) 56-64	61.0 (8.7) 50-71	59.4 (5.8) 49-71
<b>Weight (kg), mean (SD)</b>	65.3 (7.5)	71.3 (3.4)	70.5 (7.8)	68.8 (10.6)	69.2 (9.6)	68.8 (7.9)
<b>Height (cm), mean (SD)</b>	163.5 (5.5)	162.0 (6.1)	161.7 (7.6)	166.2 (5.3)	159.2 (6.8)	162.6 (6.2)
<b>BMI (kg/m<sup>2</sup>), mean (SD)</b>	24.4 (2.3)	27.3 (3.3)	26.9 (2.2)	24.9 (3.0)	27.2 (2.9)	26.1 (3.0)
<b>Hemoglobin, Screening, (g/dL), mean (SD)</b>	13.1 (0.6)	13.3 (0.5)	13.3 (0.6)	13.1 (1.0)	13.6 (0.5)	13.3 (0.6)
<b>Hemoglobin, Day -1, (g/dL), mean (SD)</b>	13.1 (0.6)	13.2 (0.6)	13.3 (0.3)	13.1 (0.9)	13.2 (0.7)	13.2 (0.6)
<b>Race, n (%)</b>						
American Indian/Alaska Native	1 (13%)	1 (17%)	0 (0%)	0 (0%)	0 (0%)	2 (6%)
Black or African American	1 (13%)	1 (17%)	0 (0%)	0 (0%)	0 (0%)	2 (6%)
White	6 (75%)	4 (67%)	6 (100%)	6 (100%)	6 (100%)	28 (88%)
<b>Ethnicity n (%)</b>						
Hispanic or Latino	2 (25%)	0 (0%)	3 (50%)	0 (0%)	2 (33%)	7 (22%)
Non-Hispanic or Latino	6 (75%)	6 (100%)	3 (50%)	6 (100%)	4 (67%)	25 (78%)

**Supplementary Table 2. Treatment-related adverse events by treatment group, n (%) of subjects**

System Organ Class Preferred Term	ACE-536 (mg/kg)				Placebo N=8
	0.0625 N=6	0.125 x 1 N=6	0.125 x 2 N=6	0.25 N=6	
<b>Musculoskeletal and Connective Tissue Disorders</b>					
Myalgia	1 (17%)	-	-	-	-
Muscle spasms	-	-	1 (17%)	-	-
<b>Skin and Subcutaneous Tissue Disorders</b>					
Pruritus generalized	-	-	-	1 (17%)	-
Rash papular	-	-	-	1 (17%)	-
Dry skin	-	-	-	1 (17%)	-
Macule	-	-	1 (17%)	-	-
<b>Nervous System Disorders</b>					
Hyperesthesia	-	-	-	1(17%)	-
<b>General Disorders and Administrative Site Conditions</b>					
Injection site hemorrhage	1 (17%)	1 (17%)	-	1 (17%)	-
Injection site macule	-	-	1 (17%)	1 (17%)	-
Injection site pain	-	-	-	-	1 (13%)

**Supplementary Table 3. Pharmacokinetic parameters for ACE-536 after administration of first SC dose by treatment group, mean (SD).**

Parameter	ACE-536 (mg/kg)		
	0.0625 (N=6)	0.125 (N=12)	0.25 (N=6)
<b>AUC<sub>0-14</sub>, day*<math>\mu\text{g/mL}</math></b>	4.7 (1.1)	6.5 (3.2)	19.6 (4.3)
<b>C<sub>max</sub>, <math>\mu\text{g/mL}</math><sup>a</sup></b>	0.4 (0.1)	0.6 (0.2)	1.9 (0.4)
<b>T<sub>max</sub>, days<sup>a</sup></b>	7.0 (2.9)	9.8 (2.6)	8.0 (3.2)
<b>t<sub>1/2</sub>, days</b>	NC	16.2 (2.2) N=7	14.9 (1.6) N=5
<b>Cl/F, mL/day/kg</b>	NA	6.4 (3.4) N=7	4.6 (0.5) N=5
<b>V<sub>z</sub>/F, mL/kg</b>	NA	142.5 (61.1) N=7	98.9 (17.2) N=5

NC = Not computable; NA = Not applicable

<sup>a</sup> compartmental analysis (otherwise, non-compartmental analysis)